<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874807</url>
  </required_header>
  <id_info>
    <org_study_id>SAND study</org_study_id>
    <nct_id>NCT02874807</nct_id>
  </id_info>
  <brief_title>Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study</brief_title>
  <acronym>SAND</acronym>
  <official_title>Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Syndrome of inappropriate antidiuresis (SIADH) is characterized by an imbalance of
      antidiuretic vasopressin (AVP) secretion. The impaired AVP regulation leads to water
      retention and secondary natriuresis and is a common cause for hyponatremia.

      The therapeutic options, aside from treating the underlying disease, depend upon the onset
      and severity of the symptoms and involve usually fluid restriction or hypertonic saline
      infusion. Alternative therapeutic options are loop diuretics, administration of oral urea or
      vasopressin receptor antagonists (vaptans). Despite those options, there are a considerable
      number of patients which do not sufficiently respond, making additional therapy necessary.

      Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-inhibitor, which is a
      new treatment option developed for patients with diabetes mellitus type 2. The SGLT2 is
      expressed in the proximal tubule and reabsorbs approximately 90 percent of the filtered
      glucose. The inhibition of SGLT2 results in renal excretion of glucose with subsequent
      osmotic diuresis. This mechanism could result in a therapeutic effect in patients with
      hypotonic hyponatremia as in SIADH.

      The aim of this study is to evaluate whether empagliflozin (Jardiance)® has an effect on the
      serum sodium levels of patients with SIADH.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum sodium</measure>
    <time_frame>4 days</time_frame>
    <description>The primary outcome is the change in serum sodium concentration from baseline to day 5, i.e. 4 days after start of treatment with study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum sodium</measure>
    <time_frame>1 day</time_frame>
    <description>Serum sodium concentration 1 day after start of Treatment with study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum sodium</measure>
    <time_frame>2 days</time_frame>
    <description>Serum sodium concentration 2 days after start of treatment with study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum sodium</measure>
    <time_frame>between day 1 to day 30</time_frame>
    <description>Serum sodium concentration at discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum sodium</measure>
    <time_frame>30 days</time_frame>
    <description>Serum sodium concentration 30 days after start of treatment with study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid intake</measure>
    <time_frame>4 days</time_frame>
    <description>amount of daily fluid intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion</measure>
    <time_frame>4 days</time_frame>
    <description>amount of daily urinary excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum electrolytes</measure>
    <time_frame>4 days</time_frame>
    <description>change of serum electrolytes from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary electrolytes</measure>
    <time_frame>4 days</time_frame>
    <description>Change of Serum electrolytes from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osmolality</measure>
    <time_frame>4 days</time_frame>
    <description>Change of Serum osmolality from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine osmolality</measure>
    <time_frame>4 days</time_frame>
    <description>Change of urinary osmolality from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose</measure>
    <time_frame>4 days</time_frame>
    <description>Change of Serum glucose from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose</measure>
    <time_frame>4 days</time_frame>
    <description>Change of urinary Glucose from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copeptin</measure>
    <time_frame>4 days</time_frame>
    <description>Change of Copeptin from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>4 days</time_frame>
    <description>Change of Aldosterone from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>4 days</time_frame>
    <description>Change of Renin from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atrial natriuretic peptide (ANP)</measure>
    <time_frame>4 days</time_frame>
    <description>Change of ANP from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-Natriuretic-Peptide (BNP)</measure>
    <time_frame>4 days</time_frame>
    <description>Change of BNP from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General well-being</measure>
    <time_frame>4 days</time_frame>
    <description>course of General well-being from baseline to day 5 as assessed by patient's self-rating score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General well-being</measure>
    <time_frame>30 days</time_frame>
    <description>course of General well-being from baseline to day 30 as assessed by patient's self-rating score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of hyponatremia</measure>
    <time_frame>4 days</time_frame>
    <description>course of hyponatremia symptoms from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of hyponatremia</measure>
    <time_frame>30 days</time_frame>
    <description>Course of hyponatremia symptoms from baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>4 days</time_frame>
    <description>Change of Body weight from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>4 days</time_frame>
    <description>Change of blood pressure from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>4 days</time_frame>
    <description>Change of heart rate from baseline to day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment escalation</measure>
    <time_frame>30 days</time_frame>
    <description>rate of Need for Treatment escalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Admission rate</measure>
    <time_frame>30 days</time_frame>
    <description>rate of Admission to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence hyponatremia</measure>
    <time_frame>30 days</time_frame>
    <description>recurrence rate hyponatremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission rate</measure>
    <time_frame>30 days</time_frame>
    <description>rate of readmission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>SIADH</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with empagliflozin 25mg once daily for four days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with Placebo once daily for four days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Hyponatremia &lt;130mmol/l due to SIADH

        Exclusion Criteria:

          -  any Treatment for SIADH during &gt;48h before study start

          -  severe illness with ICU-Admission

          -  Treatment with 3% sodium Chloride (NaCl) solution

          -  uncontrolled hypothyroidism

          -  uncontrolled adrenal insufficiency

          -  severe renal impairment (GFR &lt;30ml/min), end stage renal disease

          -  severe hepatic impairment (Child-Pugh class C)

          -  systolic blood pressure &lt;90mmHg

          -  Diabetes mellitus type 1

          -  acute myocardial infarction or chronic venous insufficiency (CVI)

          -  Treatment with SGLT2 Inhibitor, Lithium Chloride or Urea

          -  recurrent urinary-/genital tract infections

          -  contraindication for lowering blood pressure

          -  severe immunosuppression

          -  pregnancy or breastfeeding

          -  palliative care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirjam Christ-Crain, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyponatremia</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inappropriate ADH Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

